Physician profile
Howard G Osterman
NPI 1275505471
$3,252.44
in general payments reported to CMS, 2019-2025
15 companies · $120 in 2025
The $120 reported for 2025 was less than what a typical Podiatrist provider received nationally (typical 2025 total: $260).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $283 · 2020: $105 · 2021: $1,224 · 2022: $1,244 · 2023: $227 · 2024: $48.57 · 2025: $120.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $395.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $395.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supreme Orthopedic Systems, LLC | $2,414.73 | 2021-2022 | |
| Kerecis Limited | $214.25 | 2019-2023 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide, Kerecis Omega3 Marigen |
| Organogenesis INC. | $133.65 | 2019 | |
| Biopro, INC. | $105.49 | 2020 | |
| Amgen INC. | $103.08 | 2025 | Krystexxa |
| Orthofix Medical, INC. | $88.83 | 2019 | |
| Medtronic, INC. | $35.23 | 2023 | Intellis Adaptivestim |
| Zyla Life Sciences, INC. | $28.53 | 2019 | |
| Nevro Corp. | $27.85 | 2024 | Senza |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $24.11 | 2021 | |
| Pacira Pharmaceuticals Incorporated | $20.72 | 2024 | Exparel, Iovera |
| Mimedx Group, INC. | $16.95 | 2025 | |
| Kowa Pharmaceuticals America, INC. | $15.15 | 2022 | |
| Smith+Nephew, INC. | $14.42 | 2022 | |
| Musculoskeletal Transplant Foundation INC. | $9.45 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Howard Osterman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.